Ревматологические проявления постковидного синдрома (обзор литературы)
https://doi.org/10.33667/2078-5631-2022-15-20-25
Аннотация
К настоящему времени основной резонанс вызывают исследования так называемого постковидного синдрома, который может возникать даже у пациентов, перенесших COVID-19 в легкой или среднетяжелой форме. В представленном обзоре приведена историческая справка о возникновении этого термина, рассмотрены наиболее часто встречающиеся ревматологические проявления постковидного синдрома, в том числе артралгия, сыпь, перниоз, одышка, усталость, фибромиалгия, образование аутоантител и маркеров системного воспаления. В обзоре приведены также актуальные взгляды на лечение постковидного синдрома. Авторы подчеркивают необходимость дифференциальной диагностики между ревматологическими проявлениями постковидного синдрома и дебютом ревматического заболевания, возникшего после перенесенного COVID-19, и обосновывают мультидисциплинарный подход к методам терапии.
Об авторах
Е. С. Аронова
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия
Россия
Аронова Евгения Сергеевна, к.м.н., н.с. лаборатории изучения коморбидных инфекций и вакцинопрофилактики
Москва
Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия
Россия
Белов Борис Сергеевич, д.м.н. зав. лабораторией изучения коморбидных инфекций и вакцинопрофилактики
Москва
Г. И. Гриднева
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия
Россия
Гриднева Галина Игоревна, к.м.н., н.с. лаборатории изучения коморбидных инфекций и вакцинопрофилактики
Москва
Список литературы
1. Bliddal S., Banasik K., Pedersen O. B. et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep. 2021. 11. 13153. DOI: 10.1038/s41598–021–92045-x.
2. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1/06/2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6january2022
3. Perego E, Callard F, Stras L, et al. Why we need to keep using the patient made term “Long Covid”. Available at: https://blogs.bmj.com/bmj/2020/10/01/whywe-need-to-keep-using-the-patient-made-term-long-covid/ (1 October 2020)
4. Patients’ experiences of “longcovid” are missing from the NHS narrative. Available at: https://blogs.bmj.com/bmj/2020/07/10/patients-experiences-of-long-covid-are-missing-from-the-nhs-narrative/
5. Covid - 19: What do we know about “long covid”? BMJ 2020; 370: m2815. https://doi.org/10.1136/bmj.m2815
6. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Available at: https://www.nice.org.uk/guidance/ng188 (18 December 2020)
7. Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615. DOI: 10.1038/s41591–021–01283-z
8. Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594: 259–264. DOI: 10.1038/s41586–021–03553–9.
9. Phillips S., Williams M. A. Confronting our next national health disaster – long-haul Covid. N Engl J Med 2021; 385: 577–579. DOI: 10.1056/NEJMp2109285.
10. World Health Organisation (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition_Clinical_case_definition-2021.1.
11. Parums D. V. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med Sci Monit. 2021; 27: e933446. DOI: 10.12659/MSM.933446.
12. Ghosn J., Piroth. L., Epaulard O., et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021 Jul; 27 (7): 1041. e1–1041.e4. DOI: 10.1016/j.cmi.2021.03.012.
13. González-Hermosillo J.A., Martínez-López J.P., Carrillo-Lampón S.A., et al. PostAcute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. Brain Sci. 2021 Jun 8; 11 (6): 760. DOI: 10.3390/brainsci11060760.
14. Fortini A., Torrigiani A., Sbaragli S., et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021 Oct; 49 (5): 1007–1015. DOI: 10.1007/s15010–021–01638–1.
15. Karaarslan F., Güneri F. D., Kardeş S. Long COVID: rheumatologic/ musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol. 2022; 41 (1): 289–296. DOI: 10.1007/s10067–021–05942-x.
16. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 202; 324 (6): 603–605. DOI: 10.1001/jama.2020.12603.
17. Garrigues E., Janvier P., Kherabi Y., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81 (6): e4–e6. DOI: 10.1016/j.jinf.2020.08.029.
18. Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397 (10270): 220–232. DOI: 10.1016/S0140–6736(20)32656–8.
19. Moreno-Pérez O., Merino E., Leon-Ramirez J.M., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021; 82 (3): 378–383. DOI: 10.1016/j.jinf.2021.01.004.
20. Goërtz Y. M.J., Van Herck M., Delbressine J. M., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020; 6 (4): 00542–2020. DOI: 10.1183/23120541.00542–2020.
21. Peghin M., Palese A., Venturini M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021; 27 (10): 1507–1513. DOI: 10.1016/j.cmi.2021.05.033.
22. Sykes D. L., Holdsworth L., Jawad N., et al. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung. 2021; 199 (2): 113–119. DOI: 10.1007/s00408–021–00423-z.
23. Lopez-Leon S., Wegman-Ostrosky T., Perelman C., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021; 11 (1): 16144. DOI: 10.1038/s41598–021–95565–8.
24. Petersen M. S., Kristiansen M. F., Hanusson K. D. et al. Long COVID in the Faroe Islands – a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2021; 73 (11): e4058–e4063. DOI: 10.1093/cid/ciaa1792.
25. Ono K., Kishimoto M., Shimasaki T. et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020; 6 (2): e001350. DOI: 10.1136/rmdopen-2020–001350.
26. Gasparotto M., Framba V., Piovella C., et al. Post-COVID-19 arthritis: a case report and literature review. Clin Rheumatol. 2021; 40 (8): 3357–3362. DOI: 10.1007/s10067–020–05550–1.
27. Hønge B. L., Hermansen M. F., Storgaard M. Reactive arthritis after COVID-19. BMJ Case Rep. 2021. Vol. 14. Issue 3. P. e241375. DOI: 10.1136/bcr-2020–241375.
28. Аронова Е. С., Белов Б. С. Полиартрит, ассоциированный с COVID-19 (клинический случай). Современная ревматология. 2021. № 15. Том 5. С. 76–79. DOI: 10.14412/1996–7012–2021–5–76–79.
29. Derksen V. F., Kissel T., Lamers-Karnebeek F.B. et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis. 2021. Vol. 80. P. 1096–1098. DOI: 10.1136/annrheumdis-2021–219859.
30. Roongta R., Chattopadhyay A., Ghosh A. Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’ Ann Rheum Dis. 2021. epub ahead of print. DOI: 10.1136/annrheumdis-2021–220479.
31. Lerma L. A., Chaudhary A., Bryan A., Morishima C., Wener M. H., Fink S. L. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020. Vol. 3. P. 100073. DOI: 10.1016/j.jtauto.2020.100073.
32. Cares-Marambio K., Montenegro-Jiménez Y. et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021. Vol. 18. P. 14799731211002240. DOI: 10.1177/14799731211002240.
33. Wu X., Liu X., Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. Vol. 9. Issue 7. P. 747–754. DOI: 10.1016/S2213–2600(21)00174–0.
34. Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin med (Lond). 2021. Vol. 21. Issue 1. P. e63–e67. DOI: 10.7861/clinmed.2020–0896.
35. George P. M., Barratt S. L., Condliffe R. et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020. Vol. 75. P. 1009–1016. DOI: 10.1136/thoraxjnl-2020–215314.
36. McMahon D.E., Gallman A. E., Hruza G. J. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021. Vol. 21. Issue 3. P. 313–314. DOI: 10.1016/S1473–3099(20)30986–5.
37. Mehta P., Bunker C. B., Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021. Vol. 21. Issue 7. P. 912. DOI: 10.1016/S1473–3099(21)00133-X.
38. Mohabbat A. B., Mohabbat N. M.L., Wight E. C. Fibromyalgia and chronic fatigue syndrome in the age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020. Vol. 4. Issue 6. P. 764–766. DOI: 10.1016/j.mayocpiqo.2020.08.002.
39. Clauw D., Häuser W., Cohen S., Fitzcharles M. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020. Vol. 161. Issue 8. P. 1694–1697. DOI: 10.1097/j.pain.0000000000001950.
40. Wong T. L., Weitzer D. J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021. Vol. 57. Issue 5. P. 418. DOI: 10.3390/medicina57050418.
41. Graham E. L., Clark J. R.., Orban ZS. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann Clin Transl Neurol. 2021. Vol. 8. Issue 5. P. 1073–1085. DOI: 10.1002/acn3.51350.
42. Dotan A., Shoenfeld Y. Post-COVID syndrome: The aftershock of SARS-CoV-2. Int. J. Infect. Dis. 2021; 114: 233–235. DOI: 10.1016/j.ijid.2021.11.020.
43. Ursini F., Ciaffi J., Mancarella L. et al. Fibromyalgia: a new facet of the postCOVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021. Vol. 7. P. e001735. DOI: 10.1136/rmdopen-2021–001735.
44. Salaffi F., Giorgi V., Sirotti S., Bongiovanni S. et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clin. Exp. Rheumatol. 2021; 39: 72–77. PMID: 33200740.
45. Dinerman H., Goldenberg D. L., Felson D. T. A prospective evaluation of 118 patients with the fibromyalgia syndrome: Prevalence of Raynaud’s phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J. Rheumatol. 1986; 13: 368–373. PMID: 3487650.
46. Kötter I., Neuscheler D., Günaydin I., Wernet D., Klein R. Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. Rheumatol. Int. 2007; 27: 1031–1039. DOI: 10.1007/s00296–007–0413–7.
47. Dönmez S., Pamuk Ö. N., Ümit E. G., Top M. Ş. Autoimmune rheumatic disease associated symptoms in fibromyalgia patients and their influence on anxiety, depression and somatisation: A comparative study. Clin. Exp. Rheumatol. 2012; 30: 65–69. PMID: 23137613.
48. Hafiz W., Nori R., Bregasi A., Noamani B., Bonilla D. et al. Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. Arthritis Res. 2019; 21: 1–11. DOI: 10.1186/s13075–019–2013–9.
49. Peker B. O., Şener A. G., Kaptan Aydoğmuş F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J. Immunol. Methods. 2021; 499: 113174. DOI: 10.1016/j.jim.2021.113174.
50. Goebel A., Krock E., Gentry C. et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021 Jul 7; 131 (13). DOI: 10.1172/JCI144201.
51. Pascolini S., Vannini A., Deleonardi G. et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021. Vol. 14. Issue 2. P. 502–508. DOI: 10.1111/cts.12908.
52. Vlachoyiannopoulos P. G., Magira E., Alexopoulos H. et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020. Vol. 79. P. 1661–1663. DOI: 10.1136/annrheumdis-2020–218009.
53. Litwin C. M., Binder S. R. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016. Vol. 37. Issue 5. P. 439–452. DOI: 10.1080/15321819.2016.1174136.
54. Callow K. A., Parry H. F., Sergeant M., Tyrrell D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990. Vol. 105. Issue 2. P. 435–446. DOI: 10.1017/s0950268800048019.
55. Liao B., Liu Z., Tang L. et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int J Med Sci. 2021. Vol. 18. Issue 1. P. 29–41. DOI: 10.7150/ijms.49728.
56. Marvisi M., Ferrozzi F., Balzarini, et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution. Int J Infect Dis. 2020. Vol. 99. P. 485–488. DOI: 10.1016/j.ijid.2020.08.054.
57. Grech S., Borg J. N., Cuschieri S. Back pain: An aftermath of Covid-19 pandemic? A Malta perspective. Musculoskeletal Care. 2021. Epub ahead of print. P. 1–6. DOI: 10.1002/msc.1574.
58. Kamal M., Abo Omirah M., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021. Vol. 75. P. e13746. DOI: 10.1111/ijcp.13746.
59. Sudre C. H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021. Vol. 27. P. 626–31. DOI: 10.1038/s41591–021–01292-y.
60. UK Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. 2020. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications
61. Halpin S. J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021. Vol. 93. Issue 2. P. 1013–1022. DOI: 10.1002/jmv.26368.
62. Насонов Е. Л., Лила А. М., Мазуров В. И. и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021; 59 (3): 239–254.
63. Методические рекомендации. Особенности течения Long-COVID инфекции. Терапевтические и реабилитационные мероприятия. Под ред. акад. Мартынова А. И. Доступно по ссылке: https://www.rnmot.ru/public/uploads/2022/rnmot/%D0%9C%D0%95%D0%A2%D0%9E%D0%94%D0%98%D0%A7%D0%95%D0%A1%D0%9A%D0%98%D0%95%20%D0%A0%D0%95%D0%9A%D0%9E%D0%9C%D0%95%D0%9D%D0%94%D0%90%D0%A6%D0%98%D0%98.pdf
Рецензия
Для цитирования:
Аронова Е.С., Белов Б.С., Гриднева Г.И. Ревматологические проявления постковидного синдрома (обзор литературы). Медицинский алфавит. 2022;(15):20-25. https://doi.org/10.33667/2078-5631-2022-15-20-25
For citation:
Aronova E.S., Belov B.S., Gridneva G.I. Rheumatological manifestations of post-COVID syndrome (literature review). Medical alphabet. 2022;(15):20-25. (In Russ.) https://doi.org/10.33667/2078-5631-2022-15-20-25
Просмотров: 253
Послать статью по эл. почте 